Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

The efficacy of Vitamin D supplementation in the treatment of schizophrenia

Protocol summary

Summary

In this randomized clinical trial 70 patients with schizophrenia according to DSM-V criteria was divided randomly in two groups. In first group as a intervention group 35 patients received 20-25 mg olanzapine for 3 Months and 300000 IU Vitamin D as IM Injection Form for 1 Time. and other group with the same fallow up received 20-25 mg olanzapine and placebo .in each group FBS,cratinin ,ca,pr ,parathormon hormone and Positive and Negative Syndrome Scale (PANSS)Criteria at the first and the 1,2,3 Months was measured and com paired.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201507087373N5**
Registration date: **2017-05-14, 1396/02/24**
Registration timing: **retrospective**

Last update:
Update count: **0**

Registration date

2017-05-14, 1396/02/24

Registrant information

Name

Hamidreza Jamilian

Name of organization / entity

Arak University Of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 86 1222 5758

Email address

jamilian.hr@arakmu.ac.ir

Recruitment status

Recruitment complete

Funding source

Vice chancellor for research, Arak University of Medical Sciences

Expected recruitment start date

2015-08-01, 1394/05/10

Expected recruitment end date

2017-03-19, 1395/12/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

The efficacy of Vitamin D supplementation in the treatment of schizophrenia

Public title

The efficacy of Vitamin D supplementation in the treatment of schizophrenia

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: diagnosis of schizophrenia according to DSM-5 criteria ,age range 18-68 ,a score of at least 60 in PANSS Exclusion criteria:Mental Retardation; Organic brain disease; Parathyroid disorders; Use of Vitamin D Supplementation in recent 3 months; Pregnancy and Lactation; Vitamin D metabolism disorders; serum level of Vitamin D below 10 nmol/ml; serum level of Vitamin D over 100 nmol/ml; No interest to continue treatment; substance abuse; GFR below 60 ml/min; No response to previous treatment with Olanzapin; BMI over 30

Age

From **18 years** old to **68 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **70**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Arak University of Medical Sciences

Street address

Basij Square

City

ARAK

Postal code

Approval date

2015-06-29, 1394/04/08

Ethics committee reference number

IR.ARAKMU.REC.1394.93

Health conditions studied

1

Description of health condition studied

Schizophrenia

ICD-10 code

F20

ICD-10 code description

Schizophrenia

Primary outcomes

1

Description

Positive and Negative Syndrome Scale(PANSS)

Timepoint

Before intervention and every one month for 3 months

Method of measurement

Clinical Examination

Secondary outcomes

1

Description

extrapyramidal side effects

Timepoint

before intervention and every one month for 3 months

Method of measurement

clinical exam

Intervention groups

1

Description

Intervention group: receive olanzapin 10-25 mg/d for 3 months with vitamin D 300000 IU IM at the begining of intervention.

Category

Treatment - Drugs

2

Description

control group: receive olanzapine 10-25 mg/d for 3 months with placebo at the beginning of intervention.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

amir kabir hospital and emam reza clinic

Full name of responsible person

hamidreza jamilian

Street address

amir kabir hospital and emam reza clinic

City

arak

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Vice chancer for research , Arak University of Medical Sciences

Full name of responsible person

Dr.yaghoobi

Street address

Basij Square

City

ARAK

Grant name

-

Grant code / Reference number

-

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Vice chancer for research , Arak University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Hamidreza Jamilian

Position

Board of Psychiatry,Associate Professor

Other areas of specialty/work

Street address

Amir Kabir Hospital

City

ARAK

Postal code

Phone

+98 86 3313 5075

Fax

Email

jamilian.hr@arakmu.ac.ir

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

HamidReza Jamilian

Position

Board of Psychiatry

Other areas of specialty/work

Street address

Amir Kabir Hospital

City

ARAK

Postal code

Phone

+98 86 3313 5075

Fax

Email

jamilian.hr@arakmu.ac.ir

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Arak University of Medical Sciences

Full name of responsible person

Hamidreza Jamilian

Position

Board of Psychiatry ,Associate Professor

Other areas of specialty/work

Street address

Amir kabir Hospital

City

ARAK

Postal code

Phone

00

Fax

Email

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty